

# Keisuke Miyazawa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6431855/publications.pdf>

Version: 2024-02-01

60  
papers

8,930  
citations

394421

19  
h-index

161849

54  
g-index

64  
all docs

64  
docs citations

64  
times ranked

20804  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ricolinostat enhances adavosertibâ€induced mitotic catastrophe in TP53â€mutated head and neck squamous cell carcinoma cells. <i>International Journal of Oncology</i> , 2022, 60, .	3.3	7
2	BRCA1 degradation in response to mitochondrial damage in breast cancer cells. <i>Scientific Reports</i> , 2021, 11, 8735.	3.3	10
3	Azithromycin enhances the cytotoxicity of DNAâ€damaging drugs via lysosomal membrane permeabilization in lung cancer cells. <i>Cancer Science</i> , 2021, 112, 3324-3337.	3.9	22
4	Induction of synergistic nonâ€apoptotic cell death by simultaneously targeting proteasomes with bortezomib and histone deacetylase 6 with ricolinostat in head and neck tumor cells. <i>Oncology Letters</i> , 2021, 22, 680.	1.8	8
5	Targeted disruption of GAK stagnates autophagic flux by disturbing lysosomal dynamics. <i>International Journal of Molecular Medicine</i> , 2021, 48, .	4.0	12
6	Lysosomeâ€targeted drug combination induces multiple organelle dysfunctions and nonâ€canonical death in pancreatic cancer cells. <i>Oncology Reports</i> , 2021, 47, .	2.6	4
7	Vitamin K2 induces non-apoptotic cell death along with autophagosome formation in breast cancer cell lines. <i>Breast Cancer</i> , 2020, 27, 225-235.	2.9	21
8	Sequestosome 1 (p62) accumulation in breast cancer cells suppresses progesterone receptor expression via argonaute 2. <i>Biochemical and Biophysical Research Communications</i> , 2020, 531, 256-263.	2.1	5
9	Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin. <i>Biochemistry and Biophysics Reports</i> , 2020, 22, 100750.	1.3	19
10	Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines. <i>Journal of Surgical Research</i> , 2020, 250, 200-208.	1.6	7
11	Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes. <i>Cancer Science</i> , 2020, 111, 2132-2145.	3.9	46
12	Macrolide antibiotics enhance the antitumor effect of lansoprazole resulting in lysosomal membrane permeabilizationâ€associated cell death. <i>International Journal of Oncology</i> , 2020, 57, 1280-1292.	3.3	13
13	Fingolimod sensitizes EGFR wildâ€type nonâ€small cell lung cancer cells to lapatinib or sorafenib and induces cell cycle arrest. <i>Oncology Reports</i> , 2019, 42, 231-242.	2.6	8
14	Amino acid starvation culture condition sensitizes EGFR-expressing cancer cell lines to gefitinib-mediated cytotoxicity by inducing atypical necroptosis. <i>International Journal of Oncology</i> , 2018, 52, 1165-1177.	3.3	11
15	The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytotoxic effects and induces autophagy in multiple myeloma cells. <i>Leukemia and Lymphoma</i> , 2018, 59, 1439-1450.	1.3	35
16	Designing an effective drug combination for ER stress loading in cancer therapy using a real-time monitoring system. <i>Biochemical and Biophysical Research Communications</i> , 2018, 501, 286-292.	2.1	4
17	A type 2 diabetes-associated SNP in KCNQ1 (rs163184) modulates the binding activity of the locus for Sp3 and Lsd1/Kdm1a, potentially affecting CDKN1C expression. <i>International Journal of Molecular Medicine</i> , 2017, 41, 717-728.	4.0	10
18	Macrolide Antibiotics Exhibit Cytotoxic Effect under Amino Acid-Depleted Culture Condition by Blocking Autophagy Flux in Head and Neck Squamous Cell Carcinoma Cell Lines. <i>PLoS ONE</i> , 2016, 11, e0164529.	2.5	14

#	ARTICLE	IF	CITATIONS
19	Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. <i>International Journal of Oncology</i> , 2016, 48, 45-54.	3.3	38
20	Targeting bortezomib-induced aggresome formation using vinorelbine enhances the cytotoxic effect along with ER stress loading in breast cancer cell lines. <i>International Journal of Oncology</i> , 2016, 49, 1848-1858.	3.3	19
21	Specific autoantigens identified by sera obtained from mice that are immunized with testicular germ cells alone. <i>Scientific Reports</i> , 2016, 6, 35599.	3.3	13
22	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
23	Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress-mediated cell death in multiple myeloma cells. <i>International Journal of Oncology</i> , 2015, 46, 474-486.	3.3	39
24	Comparative analysis of type 2 diabetes-associated SNP alleles identifies allele-specific DNA-binding proteins for the KCNQ1 locus. <i>International Journal of Molecular Medicine</i> , 2015, 36, 222-230.	4.0	6
25	EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 461, 28-34.	2.1	54
26	Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2013, 437, 41-47.	2.1	40
27	Vitamin K2 Covalently Binds to Bak and Induces Bak-Mediated Apoptosis. <i>Molecular Pharmacology</i> , 2013, 83, 613-620.	2.3	39
28	Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. <i>International Journal of Oncology</i> , 2013, 42, 1541-1550.	3.3	87
29	Concomitant Targeting Aggresome Formation and Intracellular Proteolytic Pathways Enhances ER-Stress Mediated Cell Death In Myeloma Cells. <i>Blood</i> , 2013, 122, 4910-4910.	1.4	0
30	Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells. <i>International Journal of Oncology</i> , 2012, 40, 1029-1039.	3.3	39
31	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
32	Macrolide Antibiotics Block Autophagy Flux and Sensitize to Bortezomib Via Endoplasmic Reticulum-Stress-Mediated CHOP Induction in Myeloma Cells. <i>Blood</i> , 2012, 120, 4992-4992.	1.4	7
33	Combined treatment with bortezomib plus bafilomycin A1 enhances the cytotoxic effect and induces endoplasmic reticulum stress in U266 myeloma cells: Crosstalk among proteasome, autophagy-lysosome and ER stress. <i>International Journal of Oncology</i> , 2011, 38, 643-54.	3.3	63
34	Multicenter phase II trial of vitamin K2 monotherapy and vitamin K2 plus 1 $\alpha$ -hydroxyvitamin D3 combination therapy for low-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2010, 34, 1151-1157.	0.8	19
35	Cytoprotective effect of imatinib mesylate in non-BCR-ABL-expressing cells along with autophagosome formation. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 310-315.	2.1	16
36	Cytoprotective Autophagy Induction by Imatinib Mesylate In Non-BCR-ABL Expressing Cells. <i>Blood</i> , 2010, 116, 4937-4937.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Combined Treatment with Bortezomib Plus Bafilomycin A1 Enhances Cytocidal Effect along with Induction of ER Stress In Myeloma Cells: Crosstalk Among Proteasome, Autophagy-Lysosome, and ER Stress. <i>Blood</i> , 2010, 116, 4058-4058.	1.4	0
38	Growth inhibitory effects of vitamin K2 on colon cancer cell lines via different types of cell death including autophagy and apoptosis. <i>International Journal of Molecular Medicine</i> , 2009, 23, 709-16.	4.0	24
39	Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study. <i>International Journal of Hematology</i> , 2008, 87, 195-202.	1.6	16
40	Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia. <i>International Journal of Hematology</i> , 2008, 87, 446-448.	1.6	8
41	A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®; ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan. <i>International Journal of Hematology</i> , 2008, 88, 73-81.	1.6	40
42	Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells. <i>Autophagy</i> , 2008, 4, 629-640.	9.1	96
43	Clinical Features of Hypereosinophilic Syndrome: FIP1L1-PDGFR $\alpha$ Fusion Gene-Positive Disease is a Distinct Clinical Entity with Myeloproliferative Features and a Poor Response to Corticosteroid. <i>International Journal of Hematology</i> , 2007, 85, 5-10.	1.6	6
44	Autophagy and Apoptosis Are Induced Simultaneously in Leukemia Cells by Vitamin K2.. <i>Blood</i> , 2006, 108, 4373-4373.	1.4	0
45	Clinical Analysis of Adult Acute Leukemia with Rearrangements of the 11q23/MLL: Multicenter Co-Operative Study.. <i>Blood</i> , 2006, 108, 2354-2354.	1.4	0
46	Vitamin K2-induced antitumor effects via cell-cycle arrest and apoptosis in gastric cancer cell lines. <i>International Journal of Molecular Medicine</i> , 2006, 17, 235-43.	4.0	25
47	Peripheral T-cell lymphoma together with myelofibrosis with elevated plasma transforming growth factor- $\beta$ 1. <i>Leukemia and Lymphoma</i> , 2005, 46, 599-602.	1.3	14
48	Vitamin K2 (VK2) Monotherapy and VK2 Plus D3 Combination Therapy in Low-Risk Myelodysplastic Syndrome: A Prospective Japanese Study.. <i>Blood</i> , 2005, 106, 2528-2528.	1.4	0
49	Myelodysplastic Syndromes with Myelofibrosis May Be a Target for the JAK2 V617F Tyrosine Kinase Mutation.. <i>Blood</i> , 2005, 106, 4895-4895.	1.4	0
50	Hemophagocytic Syndrome Associated with CD8 Positive T-cell Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 193-198.	1.3	7
51	Thrombocytopenia Induced by Imatinib Mesylate (Glivec) in Patients with Chronic Myelogenous Leukemia: is 400 mg Daily of Imatinib Mesylate an Optimal Starting Dose for Japanese Patients?. <i>International Journal of Hematology</i> , 2003, 77, 93-95.	1.6	15
52	Apoptosis induction of vitamin K2 in lung carcinoma cell lines: the possibility of vitamin K2 therapy for lung cancer. <i>International Journal of Oncology</i> , 2003, 23, 627-32.	3.3	16
53	MALT Lymphoma Originating in Breast and Uvula. <i>Leukemia and Lymphoma</i> , 2001, 41, 461-463.	1.3	10
54	Myelodysplastic Syndrome Accompanied by Addison's Disease and Multiple Autoimmune Phenomena: Steroid Therapy Resolved Cytopenias and All Immune Disorders.. <i>Internal Medicine</i> , 2001, 40, 1041-1044.	0.7	13

#	ARTICLE	IF	CITATIONS
55	Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements. <i>British Journal of Haematology</i> , 2001, 114, 358-361.	2.5	35
56	Anaplastic large-cell lymphoma which showed severe inflammatory status and myelodysplasia with increased VEGF and IL-6 serum levels after long-term immunosuppressive therapy. <i>American Journal of Hematology</i> , 2001, 66, 49-52.	4.1	11
57	IgA-.LAMBDA./IgG-.KAPPA. Biclonal Myeloma in which Two Clones Proliferated in Individual Sites.. <i>Internal Medicine</i> , 2000, 39, 170-175.	0.7	4
58	Megakaryocytic Maturation is Regulated by Maintaining a Balance Against Cytokine Induced-cell Proliferation: Steel Factor Retards Thrombopoietin-induced Megakaryocytic Differentiation While Synergistically Stimulating Mitogenesis. <i>Hematology</i> , 2000, 5, 233-246.	1.5	2
59	Combination of Granulocyte Colony-Stimulating Factor and Low-Dose Cytosine Arabinoside Further Enhances Myeloid Differentiation in Leukemia Cells in Vitro. <i>Leukemia and Lymphoma</i> , 2000, 39, 173-184.	1.3	11
60	SDF-1 suppresses cytokine-induced adhesion of human haemopoietic progenitor cells to immobilized fibronectin. <i>British Journal of Haematology</i> , 1999, 106, 171-174.	2.5	18